509 results match your criteria Journal of Aerosol Medicine and Pulmonary Drug Delivery[Journal]


The Effectiveness of An Averaged Airway Model in Predicting the Airflow and Particle Transport Through the Airway.

J Aerosol Med Pulm Drug Deliv 2019 Feb 13. Epub 2019 Feb 13.

2 Department of Mechanical Science and Bioengineering, Graduate School of Engineering Science, Osaka University, Osaka, Japan.

Background: In this study, we proposed an averaged airway model design based on four healthy subjects and numerically evaluated its effectiveness for predicting the airflow and particle transport through an airway.

Methods: Direct-averaged models of the conducting airways of four subjects were restored by averaging the three-dimensional (3D) skeletons of four healthy airways, which were calculated using an inverse 3D thinning algorithm. We simulated the airflow and particle transport in the individual and the averaged airway models using computational fluid dynamics. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/jamp.2018.1500DOI Listing
February 2019

A Randomized, Double-Blinded, Placebo-Controlled, Dose-Escalation Phase 1 Study of Aerosolized Pirfenidone Delivered via the PARI Investigational eFlow Nebulizer in Volunteers and Patients with Idiopathic Pulmonary Fibrosis.

J Aerosol Med Pulm Drug Deliv 2019 Jan 30. Epub 2019 Jan 30.

1 Alfred Hospital, Department of Medicine, Monash University, Melbourne, Australia.

Background: This clinical trial evaluated the pharmacokinetics and safety/tolerability of inhaled pirfenidone solution in volunteers and patients with idiopathic pulmonary fibrosis (IPF).

Methods: Forty-four adults in six cohorts consented to receive single doses of a 12.5 mg/mL pirfenidone solution or placebo to assess tolerability and pharmacokinetics. Read More

View Article

Download full-text PDF

Source
https://www.liebertpub.com/doi/10.1089/jamp.2018.1507
Publisher Site
http://dx.doi.org/10.1089/jamp.2018.1507DOI Listing
January 2019
4 Reads

Nebulized Inhalation of Anti-Nerve Growth Factor Microspheres Inhibits Airway Remodeling in an Ovalbumin-Induced Rat Asthma Model.

J Aerosol Med Pulm Drug Deliv 2019 Jan 25. Epub 2019 Jan 25.

3 Department of Respiratory Medicine, The Second Affiliated Hospital of Guilin Medical University, Guilin, China.

Background: Airway remodeling is considered an important factor in refractory and uncontrollable asthma. Previous studies have confirmed that anti-nerve growth factor (NGF) antibody can ameliorate airway remodeling. However, whether nebulized inhalation of anti-NGF microspheres (NANM) can inhibit airway remodeling is not clear. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/jamp.2018.1453DOI Listing
January 2019

Salbutamol Nebulization During Noninvasive Ventilation in Exacerbated Chronic Obstructive Pulmonary Disease Patients: A Randomized Controlled Trial.

J Aerosol Med Pulm Drug Deliv 2018 Dec 27. Epub 2018 Dec 27.

1 Université de Tours , Tours, France .

Background: Although nebulizing beta 2-agonists during noninvasive ventilation (NIV) could prove helpful, this administration route has to date never been studied in unstable chronic obstructive pulmonary disease (COPD) patients. We sought to demonstrate that salbutamol could be nebulized through an NIV circuit in COPD exacerbation and improve forced expiratory volume in 1 second (FEV1) as compared with placebo.

Patient And Methods: This is a bench study to determine the optimal pattern of nebulization followed by a randomized double-blind parallel-group trial comparing salbutamol and placebo aerosols delivered during NIV to 43 intensive care unit patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/jamp.2018.1484DOI Listing
December 2018
4 Reads

High-Efficiency Nose-to-Lung Aerosol Delivery in an Infant: Development of a Validated Computational Fluid Dynamics Method.

J Aerosol Med Pulm Drug Deliv 2018 Dec 15. Epub 2018 Dec 15.

1 Department of Mechanical and Nuclear Engineering, Virginia Commonwealth University , Richmond, Virginia.

Background: Computational fluid dynamics (CFD) provides a powerful tool for developing new high-efficiency aerosol delivery strategies, such as nose-to-lung (N2L) aerosol administration to infants and children using correctly sized aerosols. The objective of this study was to establish numerically efficient CFD solution methods and guidelines for simulating N2L aerosol administration to an infant based on comparisons with concurrent in vitro experiments.

Materials And Methods: N2L administration of a micrometer-sized aerosol (mass median aerodynamic diameter [MMAD] = 1. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/jamp.2018.1490DOI Listing
December 2018
3 Reads

Effect of Unintentional Storage and Handling Errors of Inhaled Medications: What Does This Mean for Therapeutic Equivalence Considerations?

J Aerosol Med Pulm Drug Deliv 2018 Dec 4. Epub 2018 Dec 4.

Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, Germany.

Background: Currently, the equivalence and the substitutability of two inhaled medications are mainly driven by comparability of doses, in vitro performance, therapeutic equivalence and sameness, and handling of the inhalers. The packaging configuration is usually not considered as a factor.

Methods: Two capsule-based inhaled tiotropium-containing products that differ by their primary packaging configurations (blister versus bottle) were compared in terms of potential handling and resulting storage errors due to unintentional misuse. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/jamp.2018.1480DOI Listing
December 2018
1 Read

Pulmonary Delivery of Isoniazid in Nanogel-Loaded Chitosan Hybrid Microparticles for Inhalation.

J Aerosol Med Pulm Drug Deliv 2018 Dec 8. Epub 2018 Dec 8.

1 Department of Pharmaceutics, Faculty of Pharmacy, Helwan University , Helwan, Egypt .

Purpose: Inhalable pulmonary delivery of isoniazid (INH) may improve the efficacy and reduce drug-resistant problem.

Method: INH-loaded chitosan microparticles (Cs-Mps-1-3) were prepared as inhalable carrier for the previously prepared INH-loaded polyvinylpyrrolidone/polyitaconic acid nanoparticles (NPs) using spray-drying technique. Here, Cs-Mps-1-3 are composed of Cs: INH-loaded NPs: Free INH at w/w ratios (1:1:0), (1: 0:1), and (1:1:1), respectively. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/jamp.2018.1460DOI Listing
December 2018
1 Read

Idealhalers Versus Realhalers: Is It Possible to Bypass Deposition in the Upper Respiratory Tract?

J Aerosol Med Pulm Drug Deliv 2018 Nov 27. Epub 2018 Nov 27.

4 Aerogen Pharma , San Mateo, California.

This review discusses how advances in formulation and device design can be utilized to dramatically improve lung targeting and dose consistency relative to current marketed dry powder inhalers (DPIs). Central to the review is the development of engineered particles that effectively bypass deposition in the upper respiratory tract (URT). This not only reduces the potential for off-target effects but it also reduces variability in dose delivery to the lungs resulting from anatomical differences in the soft tissue in the mouth and throat. Read More

View Article

Download full-text PDF

Source
https://www.liebertpub.com/doi/10.1089/jamp.2018.1497
Publisher Site
http://dx.doi.org/10.1089/jamp.2018.1497DOI Listing
November 2018
23 Reads
2.395 Impact Factor

Satisfaction with the Use of eFlow Closed-System Nebulizer in Patients with Moderate-to-Very Severe Chronic Obstructive Pulmonary Disease: Findings from a Long-Term Safety Study.

J Aerosol Med Pulm Drug Deliv 2019 Feb 17;32(1):24-33. Epub 2018 Nov 17.

4 Sunovion Pharmaceuticals, Inc., Marlborough, Massachusetts.

Background: Effective delivery of inhaled drugs in chronic obstructive pulmonary disease (COPD) depends on patients' ability to correctly use an inhalation device. Nebulized delivery may be appropriate for COPD patients who cannot coordinate breath with inhalation or generate adequate inhalational force. Until recently, long-acting muscarinic antagonists (LAMAs), used for maintenance treatment of COPD, were available for delivery only via handheld inhalers. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/jamp.2018.1477DOI Listing
February 2019
3 Reads
2.395 Impact Factor

Radiolabeling an Electronic Cigarette Aerosol Using Technetium Carbon Ultrafine Particles.

J Aerosol Med Pulm Drug Deliv 2019 Feb 30;32(1):47-53. Epub 2018 Oct 30.

1 Center for Environmental Medicine, Asthma, and Lung Biology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.

Background: Electronic cigarettes (ECIGs) are widely used, but their health effects are not well known. ECIG exposure is difficult to quantify, and a direct measurement of deposition would be beneficial to in vivo and in vitro toxicity studies. The aim of this study was to demonstrate effective radiolabeling of an ECIG. Read More

View Article

Download full-text PDF

Source
https://www.liebertpub.com/doi/10.1089/jamp.2017.1442
Publisher Site
http://dx.doi.org/10.1089/jamp.2017.1442DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6354600PMC
February 2019
8 Reads

Pharmacokinetic Profile of Inhaled Submicron Particle Paclitaxel (NanoPac) in a Rodent Model.

J Aerosol Med Pulm Drug Deliv 2018 Oct 25. Epub 2018 Oct 25.

1 US Biotest, Inc. , San Luis Obispo, California.

Background: Inhaled chemotherapeutics may enhance pulmonary drug exposure to malignant lesions in the lung without substantially contributing to systemic toxicities. The pharmacokinetic profile of inhaled submicron particle paclitaxel (NanoPac) in healthy rodent plasma and lung tissue is evaluated here to determine administration proof-of-principle.

Methods: Healthy male Sprague Dawley rats received paclitaxel in one of three arms: intravenous nab-paclitaxel at 2. Read More

View Article

Download full-text PDF

Source
https://www.liebertpub.com/doi/10.1089/jamp.2018.1467
Publisher Site
http://dx.doi.org/10.1089/jamp.2018.1467DOI Listing
October 2018
15 Reads

Natural Derived Surfactant Preparation As a Carrier of Polymyxin E for Treatment of Pseudomonas aeruginosa Pneumonia in a Near-Term Rabbit Model.

J Aerosol Med Pulm Drug Deliv 2018 Oct 19. Epub 2018 Oct 19.

1 Division for Neurogeriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet , Huddinge, Sweden .

Background: Pulmonary surfactant spreads rapidly over the airway epithelium, a property that could be harnessed to transport drugs into the lungs. For efficient drug delivery, an interaction between pulmonary surfactant and the drug to be administered is likely needed. On the other hand, the interaction should not compromise the activity of surfactant or the drug once delivered in vivo. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/jamp.2018.1468DOI Listing
October 2018
15 Reads

An Open-Label Study Evaluating the Performance of the Dose Indicator in a Metered Dose Inhaler Delivering Glycopyrrolate and Formoterol Fumarate in Patients with Moderate-to-Very Severe Chronic Obstructive Pulmonary Disease.

J Aerosol Med Pulm Drug Deliv 2019 Feb 1;32(1):40-46. Epub 2018 Nov 1.

5 Pearl-a member of the AstraZeneca Group, Morristown, New Jersey.

Background: GFF MDI is a glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler formulated using co-suspension delivery technology. This open-label, single-arm multicenter study (NCT02268396) evaluated the accuracy, reliability, and functionality of the GFF MDI AeroCount dose indicator when used by patients with chronic obstructive pulmonary disease (COPD).

Patients And Methods: The study enrolled subjects (40-80 years of age) with an established clinical history (≥6 months) of COPD, who completed an electronic diary twice daily to record study-drug administration time, the number of actuations used, and pre- and post-dose dose indicator readings. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/jamp.2018.1466DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6354605PMC
February 2019
1 Read

In Vitro Flow Rate Dependency of Delivered Dose and Fine Particle Dose of Salmeterol/Fluticasone Propionate Easyhaler and Seretide Diskus with Patient Flow Rates Collected in a Randomized Controlled Trial.

J Aerosol Med Pulm Drug Deliv 2018 Oct 9. Epub 2018 Oct 9.

3 Orion Corporation , Orion Pharma, Espoo, Finland .

Background: The Easyhaler device-metered dry powder inhaler containing Salmeterol and Fluticasone propionate (S/F) has been developed for the treatment of patients with asthma and chronic obstructive pulmonary disease (COPD). We report two studies which evaluated the in vitro flow rate dependence of delivered dose (DD) and fine particle dose (FPD) of S/F Easyhaler versus Seretide Diskus.

Methods: A randomized controlled trial (RCT) assessed inspiratory flow parameters of S/F Easyhaler and Seretide Diskus in subgroups of patients with asthma (children, adolescents and adults, and elderly) and in COPD patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/jamp.2018.1463DOI Listing
October 2018
6 Reads

Intranasal Filtration of Inhaled Aerosol in Human Subjects as a Function of Nasal Pressure Drop.

J Aerosol Med Pulm Drug Deliv 2019 Feb 10;32(1):13-23. Epub 2018 Sep 10.

Department of Mechanical and Nuclear Engineering, Virginia Commonwealth University, Richmond, Virginia.

Background: Intersubject variability in nasal deposition of inhaled aerosol is significant because of the differences in nasal anatomy and breathing rate. The notable limitation of the majority of previously developed predictive correlations is including a limited number of subjects. A few recent studies have considered a wide age range of subjects, but the resulting correlations require the knowledge of the dimensions of the nasal airways and the properties of inhaled gas. Read More

View Article

Download full-text PDF

Source
https://www.liebertpub.com/doi/10.1089/jamp.2018.1476
Publisher Site
http://dx.doi.org/10.1089/jamp.2018.1476DOI Listing
February 2019
17 Reads

Effect of Nebulizer Location and Spontaneous Breathing on Aerosol Delivery During Airway Pressure Release Ventilation in Bench Testing.

J Aerosol Med Pulm Drug Deliv 2019 Feb 8;32(1):34-39. Epub 2018 Sep 8.

5 Department of Pulmonary Disease, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China.

Background: Airway pressure release ventilation (APRV) maintains a sustained airway pressure over a large proportion of the respiratory cycle, and has a long inspiratory time at high pressure. The purpose of this study was to determine the influence of the APRV with and without spontaneous breathing on albuterol aerosol delivery with a continuous vibrating-mesh nebulizer (VMN) placed at different positions on an adult lung model of invasive mechanical ventilation.

Methods: An adult lung model was assembled by connecting a ventilator with a dual-limb circuit to an 8-mm inner diameter endotracheal tube (ETT) and collecting filter attached to a test lung with set compliance of 0. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/jamp.2018.1457DOI Listing
February 2019
6 Reads

Lung Deposition of the Dry Powder Fixed Combination Beclometasone Dipropionate Plus Formoterol Fumarate Using NEXThaler Device in Healthy Subjects, Asthmatic Patients, and COPD Patients.

J Aerosol Med Pulm Drug Deliv 2018 10 10;31(5):269-280. Epub 2018 Jul 10.

2 Global Clinical Development, Chiesi Farmaceutici S.p.A , Parma, Italy .

Background: This study evaluated the lung deposition and the distribution pattern in the airways of a fixed combination of beclometasone dipropionate (BDP) and formoterol fumarate (FF) (100/6 μg) delivered as an extrafine dry powder formulation (mass median aerodynamic diameter, MMAD (μm) BDP = 1.5; FF = 1.4) through the NEXThaler device in healthy subjects, asthmatics, and patients with COPD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/jamp.2016.1359DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6161336PMC
October 2018
21 Reads

Physiologically Based Pharmacokinetic/Pharmacodynamic Modeling Accurately Predicts the Better Bronchodilatory Effect of Inhaled Versus Oral Salbutamol Dosage Forms.

J Aerosol Med Pulm Drug Deliv 2019 Feb 7;32(1):1-12. Epub 2018 Jun 7.

1 Department of Drug Metabolism and Pharmacokinetics, Respiratory, Inflammation, and Autoimmunity IMED Biotech Unit, AstraZeneca R&D, Gothenburg, Sweden.

Background: Predicting local lung tissue pharmacodynamic (PD) responses of inhaled drugs is a longstanding challenge related to the lack of experimental techniques to determine local free drug concentrations. This has prompted the use of physiologically based pharmacokinetic (PBPK) modeling to potentially predict local concentration and response. A unique opportunity for PBPK model evaluation is provided by the clinical PD data for salbutamol, which in its inhaled dosage form (400 μg), produces a higher bronchodilatory effect than in its oral dosage form (2 mg) despite lower drug concentrations in blood. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/jamp.2017.1436DOI Listing
February 2019
2 Reads

In Vitro Tests for Aerosol Deposition. VI: Realistic Testing with Different Mouth-Throat Models and In Vitro-In Vivo Correlations for a Dry Powder Inhaler, Metered Dose Inhaler, and Soft Mist Inhaler.

J Aerosol Med Pulm Drug Deliv 2018 Jun 7. Epub 2018 Jun 7.

1 School of Pharmacy, Virginia Commonwealth University , Richmond, Virginia.

Background: In vitro-in vivo correlations (IVIVC) for lung deposition may be established by testing inhalers in vitro with realistic mouth-throat (MT) models and inhalation profiles (IP). This study was designed to compare the currently available MT models and their ability to predict in vivo lung deposition.

Methods: Budelin Novolizer, Ventolin Evohaler, and Respimat fenoterol were chosen to represent a dry powder inhaler (DPI), metered dose inhaler (MDI), and soft mist inhaler (SMI) in tests using eight MT models: small, medium, and large Virginia Commonwealth University (VCU) models; small, medium, and large oropharyngeal consortium (OPC) models, the medium adult Alberta Idealized Throat (AIT), and the United States Pharmacopeia (USP) Induction Port, with IPs that simulated those used by volunteers in lung scintigraphy studies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/jamp.2018.1454DOI Listing
June 2018
33 Reads

Impact of Hypertonic Saline Solutions on Sputum Expectoration and Their Safety Profile in Patients with Bronchiectasis: A Randomized Crossover Trial.

J Aerosol Med Pulm Drug Deliv 2018 10 7;31(5):281-289. Epub 2018 Jun 7.

4 Servei de Pneumologia, Hospital Clínic de Barcelona, Universitat de Barcelona , IDIBAPS, CIBERES, Barcelona, España.

Background: The role of hyaluronic acid plus hypertonic saline (HA+HS) as a mucoactive treatment in patients with bronchiectasis is still unknown. This study evaluated whether HA+HS solution enhances similar sputum quantity with better safety profile than HS alone in patients with bronchiectasis.

Methods: In this double-blind randomized crossover trial, three solutions (7% HS; 0. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/jamp.2017.1443DOI Listing
October 2018
5 Reads

Preparation and Characterization of Doripenem-Loaded Microparticles for Pulmonary Delivery.

J Aerosol Med Pulm Drug Deliv 2018 Jun 7. Epub 2018 Jun 7.

1 Department of Pharmaceutical Technology, Faculty of Pharmacy, Istanbul University , Istanbul, Turkey .

Background: Pneumonia is a bacterial lower respiratory tract infection that has a high morbidity rate. The gram-negative pathogen Pseudomonas aeruginosa is a significant cause of nosocomial infections and ventilator-associated pneumonias and is mainly treated by carbapenems. Doripenem is a carbapenem drug, which has a broad-spectrum antibacterial activity. Read More

View Article

Download full-text PDF

Source
https://www.liebertpub.com/doi/10.1089/jamp.2017.1378
Publisher Site
http://dx.doi.org/10.1089/jamp.2017.1378DOI Listing
June 2018
16 Reads

Should Inhaler Prescriptions Also Recommend Watching Videos Showing How to Use Inhaling Devices Properly?

Authors:
Bruno Sposato

J Aerosol Med Pulm Drug Deliv 2018 10 29;31(5):321. Epub 2018 May 29.

Pneumology Department, Azienda USL Toscana Sud-Est, "Misericordia" Hospital , Grosseto, Italy .

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/jamp.2018.1470DOI Listing
October 2018
2 Reads

Flow Recirculation in Cartilaginous Ring Cavities of Human Trachea Model.

J Aerosol Med Pulm Drug Deliv 2018 May 23. Epub 2018 May 23.

1 School of Mechanical Engineering, Purdue University , West Lafayette, Indiana.

Background: Despite the prevailing assumption of "smooth trachea walls" in respiratory fluid dynamics research, recent investigations have demonstrated that cartilaginous rings in the trachea and main bronchi have a significant effect on the flow behavior and in particle deposition. However, there is not enough detailed information about the underlying physics of the interaction between the cartilage rings and the flow.

Materials And Methods: This study presents an experimental observation of a simplified Weibel-based model of the human trachea and bronchi with cartilaginous rings. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/jamp.2017.1435DOI Listing
May 2018
4 Reads

Assessment of the Power Required for Optimal Use of Current Inhalation Devices.

J Aerosol Med Pulm Drug Deliv 2018 May 23. Epub 2018 May 23.

4 Mundipharma GmbH , Limburg, Germany .

Background: Inhalation of medications is the cornerstone in the treatment of patients with lung diseases. A variety of inhalation devices exists and each device has specific requirements to achieve optimum inhalation of the drug. The goal of this study was to establish a clear overview on performance requirements of standard inhalation devices that should be met by the patient's breathing power and to develop a new method to measure the individual performance data. Read More

View Article

Download full-text PDF

Source
http://www.liebertpub.com/doi/10.1089/jamp.2017.1376
Publisher Site
http://dx.doi.org/10.1089/jamp.2017.1376DOI Listing
May 2018
11 Reads

Anatomically Based Analysis of Radioaerosol Distribution in Pulmonary Scintigraphy: A Feasibility Study in Asthmatics.

J Aerosol Med Pulm Drug Deliv 2018 10 19;31(5):298-310. Epub 2018 Apr 19.

5 Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital and Harvard Medical School , Boston, Massachusetts.

Introduction: Manual analysis of two-dimensional (2D) scintigraphy to evaluate aerosol deposition is usually subjective and has reduced sensitivity to quantify regional differences between central and distal airways.

Aims: (1) To present a method to analyze 2D scans based on three-dimensional (3D)-linked anatomically consistent regions of interest (ROIs); (2) to evaluate peripheral-to-central counts ratio (P/C) and penetration indices (PIs) for a set of 16 subjects with moderate-to-severe asthma; and (3) to compare the reproducibility of this method against one with manually traced ROIs.

Methods: Two-dimensional scans were analyzed using custom software that scaled onto 2D-projections' 3D anatomical features, obtained from population-averaged computed tomography (CT) chest scans. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/jamp.2017.1403DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6161331PMC
October 2018
7 Reads

Aerosolization of Zn-DTPA Decorporation Agent Using Jet and Ultrasonic Nebulizers.

J Aerosol Med Pulm Drug Deliv 2018 10 16;31(5):311-320. Epub 2018 Mar 16.

2 Department of Chemistry, Carleton University , Ottawa, Ontario, Canada .

Background: Chelating agents such as diethylenetriamine pentaacetic acid (DTPA) can be used as a decorporation drug in the zinc (Zn) form to treat internal radioactive contamination after exposure to plutonium or americium in a nuclear accident. Although Zn-DTPA is normally administered intravenously, inhalation of Zn-DTPA in aerosol form is a better route for direct delivery to the lungs. This work investigates the feasibility of synthesizing Zn-DTPA from three common chemicals and aerosolizing it using a jet or ultrasonic nebulizer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/jamp.2017.1419DOI Listing
October 2018
6 Reads

Regional Deposition of Particles Within the Respiratory Tract Should Be Linked to Impaction Parameter, Not Aerodynamic Size.

Authors:
Jeffry Weers

J Aerosol Med Pulm Drug Deliv 2018 04 13;31(2):116-118. Epub 2018 Mar 13.

Respira Therapeutics, Inc. , San Mateo, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/jamp.2018.1452DOI Listing
April 2018
7 Reads

Vitamin A Supplementation by Endotracheal Application of a Nano-encapsulated Preparation Is Feasible in Ventilated Preterm Lambs.

J Aerosol Med Pulm Drug Deliv 2018 12 27;31(6):323-330. Epub 2018 Mar 27.

2 Department of Pediatrics, Maastricht University Medical Center , Faculty of Health, Medicine and Lifesciences, School for Oncology and Developmental Biology (GROW), Maastricht, The Netherlands .

Background: Vitamin A (VA) is crucial for lung growth and development. In premature infants, inadequate VA levels are associated with an increased risk of bronchopulmonary dysplasia (BPD). Intramuscular VA supplementation has been shown to decrease the incidence of BPD, but is not widely used in the clinical setting due to concerns about feasibility and pain. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/jamp.2017.1438DOI Listing
December 2018
12 Reads

Bronchoscopic Improvement of Tracheobronchitis Due to Methicillin-Resistant Staphylococcus aureus After Aerosolized Vancomycin: A Case Series.

J Aerosol Med Pulm Drug Deliv 2018 12 27;31(6):372-375. Epub 2018 Mar 27.

1 Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital , Seongnam, Republic of Korea.

Background: Ventilator-associated tracheobronchitis (VAT) is an important risk factor for ventilator-associated pneumonia (VAP). The efficacy of aerosolized vancomycin (AV) in treating VAT has not been clearly demonstrated.

Methods: Four mechanically ventilated patients with methicillin-resistant Staphylococcus aureus (MRSA) pneumonia were treated with an additional AV. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/jamp.2017.1447DOI Listing
December 2018
24 Reads

Pharmacokinetics of Salmeterol and Fluticasone Propionate Delivered in Combination via Easyhaler and Diskus Dry Powder Inhalers in Healthy Subjects.

J Aerosol Med Pulm Drug Deliv 2018 10 1;31(5):290-297. Epub 2018 Mar 1.

Orion Pharma, Orion Corporation, Espoo, Finland .

Background: Easyhaler dry powder inhaler (DPI) containing salmeterol and fluticasone propionate was developed for the treatment of asthma and chronic obstructive pulmonary disease. Three different Salmeterol/fluticasone Easyhaler test products (Orion Pharma, Finland) were compared against the reference product Seretide Diskus DPI (GlaxoSmithKline, United Kingdom) to study whether any of the test products are bioequivalent with the reference.

Methods: Open and randomized pharmacokinetic four-period crossover study on 65 healthy volunteers was performed in a single center to compare the lung deposition and total systemic exposure of salmeterol and fluticasone propionate after administration of single doses (two inhalations of 50/500 μg/inhalation strength) in fasting conditions. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/jamp.2017.1437DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6161324PMC
October 2018
61 Reads

Pulmonary Delivery of Therapeutic and Diagnostic Gases.

J Aerosol Med Pulm Drug Deliv 2018 04 16;31(2):78-87. Epub 2018 Feb 16.

9 Medical R&D, Air Liquide Santé International , Les Loges-en-Josas, France .

The 21st Congress for the International Society for Aerosols in Medicine included, for the first time, a session on Pulmonary Delivery of Therapeutic and Diagnostic Gases. The rationale for such a session within ISAM is that the pulmonary delivery of gaseous drugs in many cases targets the same therapeutic areas as aerosol drug delivery, and is in many scientific and technical aspects similar to aerosol drug delivery. This article serves as a report on the recent ISAM congress session providing a synopsis of each of the presentations. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/jamp.2017.1431DOI Listing
April 2018
5 Reads

Bioavailability Study of Niosomal Salbutamol Sulfate in Metered Dose Inhaler: Controlled Pulmonary Drug Delivery.

J Aerosol Med Pulm Drug Deliv 2018 04 16;31(2):114-115. Epub 2018 Feb 16.

3 Pharmaceutical Chemistry Department, Faculty of Pharmacy, British University in Egypt , Cairo, Egypt .

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/jamp.2017.1448DOI Listing
April 2018
6 Reads

Development of an Inline Dry Powder Inhaler That Requires Low Air Volume.

J Aerosol Med Pulm Drug Deliv 2018 08 20;31(4):255-265. Epub 2017 Dec 20.

1 Department of Mechanical and Nuclear Engineering, Virginia Commonwealth University , Richmond, Virginia.

Background: Inline dry powder inhalers (DPIs) are actuated by an external air source and have distinct advantages for delivering aerosols to infants and children, and to individuals with compromised lung function or who require ventilator support. However, current inline DPIs either perform poorly, are difficult to operate, and/or require large volumes (∼1 L) of air. The objective of this study was to develop and characterize a new inline DPI for aerosolizing spray-dried formulations with powder masses of 10 mg and higher using a dispersion air volume of 10 mL per actuation that is easy to load (capsule-based) and operate. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/jamp.2017.1424DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6067687PMC
August 2018
17 Reads

Oral Versus Nasal High-Flow Bronchodilator Inhalation in Chronic Obstructive Pulmonary Disease.

J Aerosol Med Pulm Drug Deliv 2018 08 20;31(4):248-254. Epub 2017 Dec 20.

Department of Respiratory Medicine, University of Leipzig , Leipzig, Germany .

Background: Nasal high flow (NHF) alters breathing patterns, stabilizes fraction of inspired oxygen (FiO2) during respiratory distress, helps to keep up hemostasis in the airways, and washes out the upper airways. Particularly the support of inspiratory flow and decrease in functional dead space are interesting mechanisms of action with regard to aerosol delivery. Several laboratory investigations have studied aerosol delivery via the nasal route by using NHF, whereas clinical benefits are poorly evaluated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/jamp.2017.1432DOI Listing
August 2018
6 Reads

Preferences and Inhalation Techniques for Inhaler Devices Used by Patients with Chronic Obstructive Pulmonary Disease.

J Aerosol Med Pulm Drug Deliv 2018 08 5;31(4):237-247. Epub 2017 Dec 5.

1 Department of Pharmacy, Centre Hospitalier Universitaire de Sherbrooke , Sherbrooke, Canada .

Background: Inhaler technique and patient preferences are often overlooked when selecting maintenance treatments for patients with chronic obstructive pulmonary disease (COPD), but are important issues in ensuring drug efficacy and patient adherence. Few data on these issues are available for new inhalation devices.

Objectives: To evaluate the inhalation techniques for the HandiHaler, Breezhaler, Genuair, and Respimat inhalation devices, and patient preferences for the three latter inhalers that were recently developed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/jamp.2017.1409DOI Listing
August 2018
9 Reads

Harmonizing the Nomenclature for Therapeutic Aerosol Particle Size: A Proposal.

J Aerosol Med Pulm Drug Deliv 2018 04 28;31(2):111-113. Epub 2017 Nov 28.

9 University Paris Descartes (EA2511), Cochin Hospital Group (AP-HP) , Paris, France .

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/jamp.2017.1396DOI Listing
April 2018
9 Reads

Pulmonary Safety and Tolerability of Inhaled Levodopa (CVT-301) Administered to Patients with Parkinson's Disease.

J Aerosol Med Pulm Drug Deliv 2018 06 21;31(3):155-161. Epub 2017 Nov 21.

3 Acorda Therapeutics, Inc. , Ardsley, New York.

Background: CVT-301, an inhaled levodopa (LD) formulation, is under development for relief of OFF periods in Parkinson's disease (PD). Previously, we reported that CVT-301 improved OFF symptoms relative to placebo. In this study, we evaluate pulmonary function in patients treated with a single dose of CVT-301 or placebo for 3 hours, or received multiple doses/day for 4 weeks. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/jamp.2016.1354DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5994675PMC
June 2018
13 Reads

In Vitro Characterization of the eFlow Closed System Nebulizer with Glycopyrrolate Inhalation Solution.

J Aerosol Med Pulm Drug Deliv 2018 06 10;31(3):162-169. Epub 2017 Nov 10.

1 Sunovion Pharmaceuticals, Inc. , Marlborough, Massachusetts.

Background: Glycopyrrolate administered by a novel, investigational eFlow Closed System (CS) nebulizer (eFlow CS) is being evaluated for the maintenance treatment of chronic obstructive pulmonary disease (COPD). The eFlow CS is a hand-held, vibrating membrane nebulizer optimized to deliver 1 mL of glycopyrrolate solution into the lung in <3 minutes. Clinical studies have shown improvements in lung function of subjects treated with nebulized glycopyrrolate. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/jamp.2017.1384DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5994673PMC
June 2018
17 Reads

An In Vitro Examination of the Effects of Altitude on Dry Powder Inhaler Performance.

J Aerosol Med Pulm Drug Deliv 2018 08 10;31(4):221-236. Epub 2017 Nov 10.

Department of Mechanical Engineering, University of Alberta , Edmonton, Canada .

Background: The effects of altitude on dry powder inhaler (DPI) performance remain understudied. As existing standardized testing methodologies do not consider altitude, inhalation devices may be used in environments in which their performance has not been sufficiently characterized.

Methods: Six DPIs spanning a range of device resistances were examined in vitro in an environmental chamber mimicking a high-altitude environment equivalent to an altitude of 4200 m, with controls established at an altitude of 700 m. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/jamp.2017.1417DOI Listing
August 2018
22 Reads

Highlights from the 2017 IPAC-RS/ISAM Joint Workshop "New Frontiers in Inhalation Technology".

J Aerosol Med Pulm Drug Deliv 2018 08 1;31(4):199-203. Epub 2017 Nov 1.

6 Pharmaceutical Consortia Management , Drinker Biddle & Reath LLP, Washington, District of Columbia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/jamp.2017.1425DOI Listing
August 2018
7 Reads

The Rationale and Evidence for Use of Inhaled Antibiotics to Control Pseudomonas aeruginosa Infection in Non-cystic Fibrosis Bronchiectasis.

Authors:
Rajiv Dhand

J Aerosol Med Pulm Drug Deliv 2018 06 27;31(3):121-138. Epub 2017 Oct 27.

Department of Medicine, University of Tennessee Graduate School of Medicine , Knoxville, Tennessee.

Non-cystic fibrosis bronchiectasis (NCFBE) is a chronic inflammatory lung disease characterized by irreversible dilation of the bronchi, symptoms of persistent cough and expectoration, and recurrent infective exacerbations. The prevalence of NCFBE is on the increase in the United States and Europe, but no licensed therapies are currently available for its treatment. Although there are many similarities between NCFBE and cystic fibrosis (CF) in terms of respiratory symptoms, airway microbiology, and disease progression, there are key differences, for example, in response to treatment, suggesting differences in pathogenesis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/jamp.2017.1415DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5994662PMC
June 2018
18 Reads

Electronic Cigarettes: Exposure and Use Among Pediatric Populations.

J Aerosol Med Pulm Drug Deliv 2018 04 25;31(2):71-77. Epub 2017 Oct 25.

Eudowood Division of Pediatric Respiratory Sciences, Johns Hopkins Medical Institutions , Baltimore, Maryland.

As an emerging inhalational exposure, electronic cigarettes (e-cigarettes) have rapidly gained public awareness with increasing use among adolescents and adults, leading to increased primary use by adolescents and increased secondhand exposure to emissions in infants, children, and adolescents. Although the long-term health risks for primary use and secondhand emission exposure are unknown, limited data from animal studies suggest that there is the potential for long-term lung injury and altered neurocognitive development in children with exposure to nicotine-containing aerosols. In this pediatric-focused review, we discuss the history of e-cigarettes, the demographics of adolescent users, effects on health, and current legislative efforts to protect infants, children, and adolescents from exposure. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/jamp.2017.1418DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5915214PMC
April 2018
11 Reads

Aerosolizing Lipid Dispersions Enables Antibiotic Transport Across Mimics of the Lung Airway Surface Even in the Presence of Pre-existing Lipid Monolayers.

J Aerosol Med Pulm Drug Deliv 2018 08 20;31(4):212-220. Epub 2017 Oct 20.

1 Department of Chemical Engineering, Center for Complex Fluids Engineering, Carnegie Mellon University , Pittsburgh, Pennsylvania.

Background: Secondary lung infections are the primary cause of morbidity associated with cystic fibrosis lung disease. Aerosolized antibiotic inhalation is potentially advantageous but has limited effectiveness due to altered airway aerodynamics and deposition patterns that limit drug access to infected regions. One potential strategy to better reach infected areas is to formulate aerosols with surfactants that induce surface tension gradients and drive postdeposition drug dispersal via Marangoni transport along the airway surface liquid (ASL). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/jamp.2017.1412DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6067685PMC
August 2018
14 Reads

Hybrid Lipid/Polymer Nanoparticles for Pulmonary Delivery of siRNA: Development and Fate Upon In Vitro Deposition on the Human Epithelial Airway Barrier.

J Aerosol Med Pulm Drug Deliv 2018 06 16;31(3):170-181. Epub 2017 Oct 16.

2 Laboratory of Drug Delivery, Department of Pharmacy, University of Napoli Federico II , Napoli, Italy .

Background: Nowadays, the downregulation of genes involved in the pathogenesis of severe lung diseases through local siRNA delivery appears an interesting therapeutic approach. In this study, we propose novel hybrid lipid-polymer nanoparticles (hNPs) consisting of poly(lactic-co-glycolic) acid (PLGA) and dipalmitoyl phosphatidylcholine (DPPC) as siRNA inhalation system.

Methods: A panel of DPPC/PLGA hNPs was prepared by emulsion/solvent diffusion and fully characterized. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/jamp.2017.1364DOI Listing
June 2018
38 Reads

Homogeneity of Aerosol Deposition and Mucociliary Clearance are Improved Following Ivacaftor Treatment in Cystic Fibrosis.

J Aerosol Med Pulm Drug Deliv 2018 08 16;31(4):204-211. Epub 2017 Oct 16.

1 Department of Medicine, University of North Carolina , Chapel Hill, North Carolina.

Background: Using planar gamma scintigraphy of inhaled radioaerosols, we have developed new analytical methods for assessing homogeneity of aerosol deposition and time-dependent particle clearance on a pixel-by-pixel basis, and applied them to a therapeutic cystic fibrosis (CF) study.

Methods: At baseline and 1 month after beginning treatment with ivacaftor, a cystic fibrosis transmembrane regulator modulator for CF patients with at least one copy of the G551D mutation (n = 13), initial deposition and subsequent mucociliary clearance (MCC) of radiolabeled particles (Technetium-sulfur colloid, 5 μm mass median aerodynamic diameter) inhaled under controlled breathing conditions were measured.

Results: Improved homogeneity of deposition, that is, decreased areas of higher and lower particle deposition in the lungs, was observed following ivacaftor treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/jamp.2017.1388DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6067688PMC
August 2018
22 Reads

Use of a Remote Inhaler Monitoring Device to Measure Change in Inhaler Use with Chronic Obstructive Pulmonary Disease Exacerbations.

J Aerosol Med Pulm Drug Deliv 2018 06 16;31(3):191-198. Epub 2017 Oct 16.

3 Department of Health Services Research and Development, VA Puget Sound Health Care System , Seattle, Washington.

Background: Remote inhaler monitoring is an emerging technology that enables the healthcare team to monitor the time and location of a patient's inhaler use. We assessed the feasibility of remote inhaler monitoring for chronic obstructive pulmonary disease (COPD) patients and the pattern of albuterol inhaler use associated with COPD exacerbations.

Methods: Thirty-five participants with COPD used an electronic inhaler sensor for 12 weeks which recorded the date and time of each albuterol actuation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/jamp.2017.1383DOI Listing
June 2018
22 Reads
1 Citation
2.400 Impact Factor

Critical Parameters for Particle-Based Pulmonary Delivery of Chemotherapeutics.

J Aerosol Med Pulm Drug Deliv 2018 06 12;31(3):139-154. Epub 2017 Oct 12.

4 Department of Chemistry, Faculty of Science, University of Malaya , Kuala Lumpur, Malaysia .

Targeted delivery of chemotherapeutics through the respiratory system is a potential approach to improve drug accumulation in the lung tumor, while decreasing their negative side effects. However, elimination by the pulmonary clearance mechanisms, including the mucociliary transport system, and ingestion by the alveolar macrophages, rapid absorption into the blood, enzymatic degradation, and low control over the deposition rate and location remain the main complications for achieving an effective pulmonary drug delivery. Therefore, particle-based delivery systems have emerged to minimize pulmonary clearance mechanisms, enhance drug therapeutic efficacy, and control the release behavior. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/jamp.2017.1382DOI Listing
June 2018
31 Reads